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tive. However, they are not routinely considered in treatment planning as they are
not readily visualized on treatment planning CTs (TPCTs). This work integrated the
soft tissue contrast provided by low‐ﬁeld MRIs acquired on an MR‐linac via image
registration to further enable cardiac substructure sparing on TPCTs.
Methods: Sixteen upper thoracic patients treated at various breathing states (7
end‐exhalation, 7 end‐inhalation, 2 free‐breathing) on a 0.35T MR‐linac were retrospectively evaluated. A hybrid MR/CT atlas and a deep learning three‐dimensional
(3D) U‐Net propagated 13 substructures to TPCTs. Radiation oncologists revised
contours using registered MRIs. Clinical treatment plans were re‐optimized and evaluated for beam arrangement modiﬁcations to reduce substructure doses. Dosimetric
assessment included mean and maximum (0.03cc) dose, left ventricular volume
receiving 5Gy (LV‐V5), and other clinical endpoints. As metrics of plan complexity,
total MU and treatment time were evaluated between approaches.
Results: Cardiac sparing plans reduced the mean heart dose (mean reduction
0.7 ± 0.6, range 0.1 to 2.5 Gy). Re‐optimized plans reduced left anterior descending
artery (LADA) mean and LADA0.03cc (0.0–63.9% and 0.0–17.3 Gy, respectively).
LV0.03cc was reduced by >1.5 Gy for 10 patients while 6 cases had large reductions
(>7%) in LV‐V5. Left atrial mean dose was equivalent/reduced in all sparing plans
(mean reduction 0.9 ± 1.2 Gy). The left main coronary artery was better spared in
all cases for mean dose and D0.03cc. One patient exhibited >10 Gy reduction in
D0.03cc to four substructures. There was no statistical difference in treatment time
and MU, or clinical endpoints to the planning target volume, lung, esophagus, or
spinal cord after re‐optimization. Four patients beneﬁted from new beam arrangements, leading to further dose reductions.
Conclusions: By introducing 0.35T MRIs acquired on an MR‐linac to verify cardiac
substructure segmentations for CT‐based treatment planning, an opportunity was
presented for more effective sparing with limited increase in plan complexity. Validation in a larger cohort with appropriate margins offers potential to reduce radiation‐related cardiotoxicities.

---------------------------------------------------------------------------------------------------------------------------------------------------------------------This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
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1 | INTRODUCTION

To date, reducing dose to sensitive cardiac substructures has
been severely limited because they are not readily visible on stan-

Cardiac toxicity is a major complication of cancer treatment and

dard x‐ray‐based imaging used for both RT planning (i.e., computed

can occur during, shortly after, and even many years after treat-

tomography simulation (CT‐SIM)) and RT delivery (i.e., cone‐beam CT

ment has been delivered. Long‐term follow‐up of patients undergo-

(CBCT)). Thus, leveraging the superb soft‐tissue contrast of magnetic

ing thoracic radiation, such as lymphoma, lung, breast, and

resonance imaging (MRI) may be advantageous as MRI improves car-

esophageal cancers, has shown that in particular, radiation therapy

diac substructure visibility.16,17 Furthermore, the recent introduction

(RT) can lead to radiation‐induced cardiac toxicities such as conges-

of MRI guided linear accelerators (MR‐linacs, Fig. 1 left) has yielded

tive heart failure, pericardial effusion, coronary artery disease, and

improved tumor and critical structure visualization at 0.35T MRI as

myocardial infarction.1‐3

compared to CBCT.18 MRgRT allows for continuous anatomical visu-

Yet, when a patient’s RT plan is created, only simple whole heart

alization of the patient’s heart and target volume throughout treat-

metrics (i.e., mean heart dose (MHD)) are routinely considered for

ment which may offer advantages for improved cardiac sparing.

cardiac risk assessment in the current standard of care. The Quanti-

Therefore, to advance toward mitigating cardiotoxic side effects

tative Analysis of Normal Tissue Effects in the Clinic (QUANTEC)

from RT, approaches for considering cardiac substructures during

report assesses dose to the heart as a whole and recommends <10%

treatment planning are urgently needed.

of it receives >25 Gy as the endpoint of long‐term cardiac mortal-

This work sought to apply a multimodality workﬂow (treatment

ity.4 Importantly, these whole‐heart dose metrics do not provide any

planning CTs coupled with low‐ﬁeld MR‐linac MRIs) to integrate sen-

information on where dose is distributed.

sitive cardiac substructures into treatment planning. This multimodal-

The heart is a complex organ and dose to its substructures (e.g.,

ity workﬂow allowed us to quantify potential dosimetric advantages

coronary arteries, ventricles, atria, great vessels) have been strongly

for improved cardiac sparing through plan re‐optimization and for

associated with radiation‐induced cardiac morbidity5 and future

cases that may beneﬁt, beam angle modiﬁcations.

acute coronary events.6,7 For example, dose to the left anterior
descending artery (LADA) has been linked to an increased risk of
myocardial infarction8 and development of coronary artery calciﬁcations.9 Similarly, higher doses at the base of the heart (i.e., ascending
aorta, superior vena cava, and pulmonary artery) are associated with

2 | METHODS
2.A | Patient cohort and image acquisition

lower rates of patient survival.10 Importantly, recent RTOG 0617

Fifteen patients with 16 pericardial lesions (i.e., 16 individual plans)

subanalyses suggest that dose to the atrial and ventricular cardiac

who underwent MR‐guided RT for upper thoracic treatments of the

substructures are more strongly associated with survival than assess-

lung, mediastinum, and esophagus were retrospectively reviewed on

ing dose/volume relationships to the entire heart volume.11‐13 In a

an Institutional Review Board approved study. Of these, 11 were

recent study by van den Bogaard,6 dose to the left ventricular vol-

treated with stereotactic body radiation therapy (3–5 fractions to a

ume receiving 5 Gy predicted major coronary events better than

total dose of 30–50 Gy), 2 underwent conventional fractionation

MHD. A study by Hoppe et al. highlighted the importance of quanti-

(25–35 fractions to a total dose of 50–70 Gy), and the remaining 3

fying substructure dose as the MHD becomes less correlated to sub-

were moderately hypofractionated (14–20 fractions to a total dose

structure dose with increasingly conformal delivery.14 Furthermore, a

of 36–60 Gy). Patients were imaged in various breathing states (7

study by Jacob et al. outlines how the MHD does not accurately

end‐exhalation, 7 end‐inhalation, 2 free‐breathing) on a 0.35T View-

predict dose to the left ventricle (LV) and coronary arteries.15

Ray MRIdian linear accelerator (ViewRay, Mountain View, CA).

F I G . 1 . (Left) ViewRay 0.35T MR‐linac,
(middle) treatment planning CT, and (right)
0.35T MR dataset with cardiac
substructure contours evident and
delineated. PTV: planning target volume
(malignant neoplasm of lower left lung
bronchus). Cardiac‐related abbreviations
are deﬁned in the text.
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All patients were imaged with a balanced steady‐state free pre-

3

therapy (IMRT) planning was used to generate all 16 RT plans at a

cession (bSSFP), TrueFISP acquisition sequence (Siemens, MAGNE-

dose rate of 600 cGy/min. The MR‐linac utilizes a fast Monte Carlo

TOM Avanto, Syngo MR B19) with 15/16 patients with mobile

dose calculation algorithm25 and plans were calculated using a

tumors undergoing daily 17–25 sec MRIs (1.5 × 1.5 × 3 mm3) under

1 × 1 mm dose grid with 1% dose uncertainty.26 Plans were pre-

breath‐hold conditions. One patient with a left chest wall lesion

scribed to 95% of the planning target volume with total doses for

could not tolerate breath‐hold and thus underwent a 175‐second

the original treatment plans varying from 30 to 70 Gy delivered in

free‐breathing MRI for treatment planning. TrueFISP is commonly

4–35 fractions. The original treatment plans for all patients included

used in cardiac imaging due to high signal‐to‐noise ratio and impervi-

clinical dose constraints for whole heart endpoints. All clinical treat-

ousness to motion artifacts.19,20 All treatment planning was con-

ment plans met physician objectives using standard QUANTEC27,28

ducted and dose was calculated on a non‐contrast CT‐SIM in a

and TG‐10129 dosimetric endpoints for OARs.

manner similar to what has been reported for MR‐guided RT of tho21

Along with adding substructure segmentations retrospectively to

All CT‐SIMs were acquired on a Brilliance Big Bore

the original clinical treatment plans for dose assessment, all plans

CT Simulator (Philips Medical Systems, Cleveland, OH) with a 3‐mm

were re‐optimized to spare cardiac substructures (SPARE plan).

slice thickness. MR and CT‐SIM sessions were conducted on the

Strategies for substructure sparing included evaluating the original

same day and patients were immobilized in the supine position using

plan to identify which cardiac substructures were near the planning

molded vacuum cushions.

target volume (PTV) and thus received the most dose. Optimization

racic lesions.

objectives were then added with increased priority on the substruc-

2.B | Segmentation and registration

tures receiving higher doses. If the dose limit was unachievable, constraints were relaxed with the overall objective to minimize

Assessed cardiac substructures included the heart, left/right ventri-

substructure dose. If the dose to a particular substructure was mini-

cles (LV, RV), atria (LA, RA), superior/inferior venae cavae (SVC, IVC),

mal in the original plan, an additional objective was added in the

ascending aorta (AA), pulmonary artery/veins (PA, PV), left anterior

IMRT optimization to ensure consistency was maintained.

descending artery (LADA), right coronary artery (RCA), and left main

In addition to adding substructures to the optimization, possible

coronary artery (LMCA). For 11 patients, a cardiac substructure seg-

further cardiac sparing improvement was also assessed through mod-

mentation atlas22 automatically generated the cardiac substructures

ifying the beam arrangement (New Angles plan) after the substruc-

on the CT‐SIM dataset for treatment planning with the ﬁnal con-

tures had already been incorporated into the optimization. For plans

tours displayed on the low‐ﬁeld MRI at Fig. 1, right. For the remain-

with lesions that are particularly close in proximity to the heart, it

ing ﬁve patients evaluated at a later date, automatic cardiac

was evaluated whether beams entering or exiting the heart could be

substructure segmentation on the CT‐SIM was performed using a

potentially removed or modiﬁed to further spare the heart and sub-

three‐dimensional U‐Net,23 a deep learning model that improved the

structures. IMRT techniques were used for all SPARE and New

accuracy and substructure generation time as compared to the atlas

Angles plans with the substructures integrated into the optimization

method.

while maintaining tumor volume coverage and minimizing organ at

While automatic segmentation methods (i.e., multi‐atlas and deep

risk (OAR) dose. Table 1 outlines the dosimetric considerations

learning methods) provided initial substructure contours on the CT‐

T A B L E 1 Summary of cardiac substructure sparing objectives
utilized in planning optimization for the re‐optimization (SPARE) plan
and the New Angles plan.

SIM datasets, a radiation oncologist consulted the co‐registered low‐
ﬁeld MRI to modify and conﬁrm the ﬁnal contours used for treatment planning. As shown by the lack of contrast in the planning CT
(Fig. 1, center), the enhanced soft tissue contrast from the MRI

Substructure

Mean Dose

Maximum
Dose

Additional
Endpoint

assisted the generation of more reliable cardiac substructure delin-

Right ventricle

‐

Minimize13

V4513

Left ventricle

‐

Minimize

13

Left atrium

8.5 Gy10
Minimize13,31

Minimize30

V4513

multimodality images.24

Right atrium

8.5 Gy10
Minimize13

‐

V4513

2.C | Treatment planning

Superior vena
cava

8.5 Gy10

‐

D9030

For all patients, the CT‐SIM was used as the primary image set for

PA, PV, AA

8.5 Gy10

eations on the corresponding planning CT. Co‐registration involved
an automatic rigid registration based off a manually drawn, local, cardiac conﬁned bounding box. Normalized mutual information was
used as the similarity metric as it has been shown to accurately align

treatment planning as has been reported in the literature for MRgRT
of thoracic lesions.21 The co‐registration of the low‐ﬁeld MR image
to the CT‐SIM to elucidate the cardiac substructures was a critical
step in allowing the physician to verify the cardiac substructure
autosegmentations. Step‐and‐shoot intensity modulated radiation

Left anterior
descending artery

Minimize

RCA, LMCA

‐

LV‐V56
V4513

‐
32

< 10 Gy33
Minimize

V4513

‐

V4513

Minimize may be taken as “as low as reasonably achievable” (ALARA).
Abbreviations deﬁned in the text.

4

|

MORRIS

ET AL.

during plan optimization, derived from the literature, when cardiac

adjacent to the heart (i.e., a pericardial lymph node and a malignant

substructures were included. All plans were converted to standard

neoplasm of the lung (Fig. 5)). The other two patients presented with

fractionation using the equivalent dose to 2 Gy fractions (EQD2, α/

upper lung lobe lesions that were greater than 9 cm away from the

β = 2) to allow for uniform evaluation.

heart. The average treatment time for these patients after beam angle
modiﬁcation was 6.12 ± 3.68 minutes, which was not signiﬁcantly dif-

2.D | Dosimetric and statistical assessment

ferent (P > 0.05) from the original treatment time for these 4 patients
(6.54 ± 3.31 minutes). Lastly, the mean percent difference in the deliv-

Original, SPARE, and when applicable, New Angle plans were

ered MUs between the original and re‐optimized plans for these

exported from the ViewRay planning system and imported into MIM

patients was 9.5 ± 16.8% (range −16.6 to 23.8%, P > 0.05).

(version 6.9.4, MIM Software Inc., Cleveland, OH) for automated
evaluation. Dosimetric assessment included mean doses, left ventricular volume receiving 5 Gy (LV‐V5), and Dose to 0.03 cc (D0.03cc,

3.B | Cardiac Substructure Sparing

surrogate for maximum dose) for 12 cardiac substructures and the

The radiation dose to the whole heart after plan re‐optimization

whole heart. To ensure clinically acceptable plans were still achieved,

met all clinical objectives.27,28 All sparing plans signiﬁcantly reduced

differences in PTV coverage and dose to the OARs were also

the MHD (P < 0.05) with an average reduction of 0.7 ± 0.6 Gy

assessed. Lastly, total MU and treatment time were evaluated and

(range 0.1 to 2.5 Gy). Furthermore, D0.03cc to the heart was reduced

compared to the original clinical treatment plan as metrics of plan

by 8.6 ± 12.1 Gy (range −8.6 to 39.9 Gy) across all patients after

complexity. All dosimetric and planning data were summarized via

plan re‐optimization (P < 0.05).

mean ± standard deviation (SD). As the data were not normally dis-

Fig. 2 outlines a subset of dose objectives from Table 1 repre-

tributed, dosimetric comparisons at each metric were conducted

senting the difference in radiation dose received by the LADA, LA,

using a two‐tailed Wilcoxon signed ranks test with P < 0.05 consid-

and LV between the original and clinical treatment plans across all

ered statistically signiﬁcant. Statistical assessments were conducted

16 patients. Re‐optimized SPARE plans reduced LADA mean and

in SPSS version 25.0 (SPSS, Chicago, IL).

D0.03cc by anywhere from 0.0 to 4.0 Gy and from 0.0 to 17.3 Gy,
respectively (Fig. 2 left). For the 5 patients that had LADA0.03cc
doses greater than 10 Gy (threshold for coronary artery calciﬁcation9

3 | RESULTS

presented in Table 1), 4 were brought below 10 Gy after re‐opti-

3.A | Contour generation and plan complexity

mization (average reduction for these patients was 13.4 ± 7.0 Gy).
D0.03cc for the remaining patient was reduced from 29.0 to 11.2 Gy.

The treatment time per fraction (a metric of plan complexity) across

Similarly, D0.03cc to the LV was reduced in 14 cases (range 0.05–

the 16 patients after plan re‐optimization was 6.57 ± 3.50 minutes

12.85 Gy) with 10 patients having >1.5 Gy reductions. There was a

(range 2.60–12.41) for the clinical treatment plan and was

large reduction (>7%) in LV‐V5 for 6 patients with an initial LV‐V5

6.93 ± 3.27 minutes

re‐optimizing

greater than 10%. LA mean dose (Fig. 2, center) was either equiva-

(P > 0.05). The mean percent difference in the delivered MUs

lent or reduced (average reduction 0.9 ± 1.2 Gy) for all SPARE plans.

between the original and re‐optimized plans was 1.7 ± 11.3% (range

For Patient 3, the left atrial mean dose was reduced to <8.5 Gy

−21.6 to 15.8%) which did not yield a statistically signiﬁcant differ-

which has been shown to be a threshold associated with decreased

ence (P > 0.05).

survival,10 and highlights the importance of optimizing plans while

(range

2.75–11.99)

after

Four patients beneﬁted from New Angles plans where the number

considering these thresholds. Lastly, the left atrial maximum dose,

of original treatment beams (range 7–11) shifted by anywhere from −1

which has been signiﬁcantly associated with non‐cancer death,30

to + 3 (range 8–14). For two of the four patients, lesions were directly

was reduced by 2.3 ± 6.4 Gy across all 16 patients.

F I G . 2 . Dose sparing possible by incorporating cardiac substructures into IMRT optimization during MR‐guided radiation therapy planning.
The mean dose for all 16 patients is shown for the left anterior descending artery (left) and the left atrium (center). The left ventricular volume
receiving 5 Gy (LV‐V5) is shown on the right.
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Table 2 summarizes the change in mean dose and D0.03cc to all
cardiac substructures. The mean doses to all substructures and the
heart were signiﬁcantly reduced after re‐optimization (P < 0.05).

5

3.C | Organs at risk (OARs) and planning target
volume (PTV) coverage

Moreover, D0.03cc was signiﬁcantly reduced after plan re‐optimiza-

All re‐optimized plans met the original clinical prescription dose to

tion in 8 out of 12 substructures, as well as for the whole heart. The

the PTV while doses to the OARs met all objectives based on clini-

LMCA mean and D0.03cc doses were reduced for all patients and

cally acceptable guidelines.27,28 Table 2 outlines the average change

were the substructure with the largest reduction in mean dose

in the mean dose and D0.03cc for the PTV and OARs. Across all

across all patients (average reduction in LMCA mean dose:

patients, the esophagus had a negligible change in mean dose after

1.13 ± 1.15 Gy). Lastly, the volume of the heart receiving 25 Gy

plan re‐optimization (0.25 ± 0.70 Gy, P > 0.05). Additionally, differ-

(V25) was signiﬁcantly reduced on average (n = 11 patients who met

ences in clinical endpoints such as the volume of the lung receiving

the V25 threshold) by 1.08 ± 1.47% (P < 0.05).

20 Gy (V20) and volume of the esophagus receiving 35 Gy (V35)

Further cardiac substructure dose sparing beyond re‐optimization

were negligible after re‐optimization (P > 0.05). No statistically sig-

was achieved for 4 patients with beam angle modiﬁcation where the

niﬁcant changes were observed in the mean dose, D0.03cc, and other

mean dose reduction across all substructures was 0.6 ± 0.4 Gy (high-

clinical endpoints for the PTV and OARs (P > 0.05). Although the

est mean reduction was in the PA and was 1.5 ± 2.0 Gy). The

increase in PTV D0.03cc was not statistically signiﬁcant, target

D0.03cc, mean dose, and V25 to the heart were further reduced by

homogeneity may still be decreased a non‐negligible amount due to

5.4 ± 4.1 Gy, 0.5 ± 0.7 Gy, and 4.2 ± 2.9%, respectively. For the LV,

plan re‐optimization.

after re‐optimization coupled with beam angle modiﬁcation, D0.03cc

For the four patients that beneﬁted from beam angle modiﬁca-

and LV‐V5 were further reduced by 2.1 ± 2.9 Gy and 2.0 ± 1.9%,

tion, negligible changes were observed for all of the PTV D95 met-

respectively. Lastly, the SVC D90 improved 3.3 ± 4.0% after the

rics (range 0 to 0.30 Gy) and three out of four patients’ D0.03cc

beam angles were modiﬁed.

(<0.5 Gy). However, one patient had an increase in D0.03cc of 3.7%,

T A B L E 2 Change in D0.03cc and mean dose after plan re‐optimization for the PTV, heart and its substructures, and other organs at risk.
Average change After re‐optimization

Structure

Mean dose (Gy)
PTV

Organs at Risk

Heart and Substructures

Spinal Cord

0.37 ± 1.85
0.06 ± 0.25

Total lung

−0.01 ± 0.26

Esophagus

0.25 ± 0.70

D0.03cc (Gy)
Other clinical endpoint
1.95 ± 3.67
PTV95: 0.03 ± 0.21 Gy
0.38 ± 1.37
1.32 ± 2.70
V20: 0.03 ± 0.71 %
0.39 ± 4.06
V35: 0.53 ± 2.46 % (n = 5)

Heart

−0.68 ± 0.60*

−8.57 ± 12.06*
V25: −1.08 ± 1.47* % (n = 11)

LV

−0.53 ± 0.70*

−3.27 ± 4.08*
LV−V5: −6.33 ± 5.57* % (n = 12)

LA

−0.85 ± 1.22*

−2.30 ± 6.42

RV

−0.55 ± 0.74*

−4.12 ± 4.81*

RA

−0.52 ± 0.94*

−1.38 ± 4.47

AA

−0.83 ± 1.13*

−2.23 ± 3.42*

PA

−0.95 ± 1.60*

−2.84 ± 8.53

PV

−0.89 ± 1.09*

−2.71 ± 5.69*

SVC

−0.57 ± 1.19*

−1.08 ± 3.65*
D90: −0.10 ± 1.23 Gy*

IVC

−0.16 ± 0.38*

−0.74 ± 1.91

LADA

−0.91 ± 1.18*

−4.05 ± 5.32*

LMCA

−1.13 ± 1.15*

−1.31 ± 1.55*

RCA

−0.65 ± 1.26*

−1.64 ± 3.38*

The asterisk indicates signiﬁcant reduction in dose after re‐optimization (none of the increases represented here were statistically signiﬁcant). N = 16
for all structures except for the esophagus where n = 10. For the heart V25, esophagus V35, and LV‐V5, results were reported only for structures with
a non‐zero value for the corresponding dosimetric endpoint. Abbreviations are deﬁned in the text.
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Fig. 3 highlights that for the patients shown, negligible differences

the original clinical treatment plan. Negligible changes (<1%) in clini-

(<1 Gy) were observed for the mean lung dose and D0.03cc to the

cal endpoints were observed for the esophagus (V35 and V50) and

spinal cord indicating comparable plan quality was achieved even

lungs (mean dose and V20) as compared to the original clinical treat-

when cardiac substructure sparing was implemented. Radiation doses

ment plan while the spinal cord D0.03cc was reduced by 2.3 ± 1.9 Gy

to the whole heart and total lung (results not shown for all patients)

with beam angle modiﬁcation as compared to re‐optimization alone.

were reduced for all patients after re‐optimization, with even further
reductions after beam angles were modiﬁed. For Patient 2, the mean

3.D | Individual patient results

esophageal dose decreased by 3.0 Gy from the original clinical plan
and 4.5 Gy from the re‐optimized plan after modifying the beam

Fig. 3 shows dose–volume histograms (DVHs) for three patients

angles, all while reducing the mean dose to the AA, SVC, RA, and

selected to represent an example of the least effective cardiac sub-

LMCA by more than 5 Gy.

structure sparing (Patient 1), highly effective sparing (Patient 2), and

Fig. 4 illustrates the initial clinical treatment plan of a malignant

an average case (Patient 13). Each DVH shows the PTV, involved

neoplasm of the lower left lung bronchus (left) treated to 48 Gy in

OARs, and relevant cardiac substructures for both the original clinical

four fractions and the corresponding cardiac SPARE treatment plan

treatment plan and the re‐optimized plan. Patient 2 beneﬁted from

(right) for Patient 11. This ﬁgure highlights cardiac substructure spar-

beam angle modiﬁcations, and thus, that plan is represented as well.

ing with > 10 Gy reductions in D0.03cc to the LV, LA, and PV.

F I G . 3 . Dose–volume histograms (DVH)
for three patients of the least effective
cardiac substructure sparing (Patient 1),
highly effective sparing (Patient 2), and an
average case (Patient 13) showing dose
from the original clinical treatment plan
and after re‐optimization. The modiﬁed
beam angle plan is also shown for Patient
2. Abbreviations deﬁned in the text.
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F I G . 4 . (Left) Initial clinical treatment
plan, (middle) corresponding cardiac SPARE
treatment plan, and (right) a difference
map of initial minus SPARE for Patient 11.
Abbreviations deﬁned in the text.

Speciﬁcally, note the removal of the 5 and 10 Gy isodose lines from

reﬂect the local dose deposition that the substructure metrics are

many heart substructures (LA, AA, RA, PV, and RV) after the re‐opti-

able to capture. For example, the LV‐V5 was reduced from 30.6% to

mization.

14.7% after re‐optimization. Furthermore, the mean dose to the AA

Fig. 5 shows the clinically used radiation treatment plan for

was reduced by ~ 6 Gy and the LADA D0.03cc was reduced below

Patient 2 (DVH also shown in Fig. 3) that originally met all whole‐

10 Gy (threshold for coronary artery calciﬁcation9 presented in

heart dose endpoints for a locally advanced lung cancer patient trea-

Table 1) with sparing.

ted to 60 Gy in 20 fractions. Cardiac sparing after re‐optimization is

Optimal beam arrangements led to further cardiac substructure

shown with the original clinical treatment plan shown (top left), the

dose reduction in 4 patients. Fig. 6 shows the original clinical plan

cardiac SPARE plan (top right), and the difference map (bottom left).

(left), re‐optimized SPARE plan (center), and New Angles plan (right)

The dose metric table (bottom right) highlights that standard whole

for Patient 5 who had a left lung cancer treated to 48 Gy in 4 frac-

heart dose metrics (<3 Gy and <2% absolute difference) do not

tions. This ﬁgure shows that although there was a slight change for

F I G . 5 . Top row: (Left) Clinically treated
plan for an advanced stage lung cancer
patient. (Right) Cardiac substructure spared
plan. Bottom row: (Left) Dose difference
map (clinical less cardiac spared plan)
highlighting major dose reductions to
cardiac substructures. (Right) Dose metric
table showing select standard whole heart
dose metrics and substructure metrics.
Maximum dose deﬁned as dose to 0.03 cc
volume. Abbreviations deﬁned in the text.
DVH shown in Fig. 3.

F I G . 6 . Top row: Original clinical plan
(left), re‐optimized SPARE plan (center),
and New Angles plan (right) for a patient
with a left lung tumor. Bottom row:
Difference maps comparing the re‐
optimized SPARE plan and the New Angles
plan to the original clinical plan. Difference
maps are the original plan less the new
plan. Abbreviations are deﬁned in the text.

8

|

MORRIS

ET AL.

the cardiac substructures after plan re‐optimization (mean reduction

based treatment planning modalities as our atlas and deep learning

in mean dose over all substructures: 0.2 ± 2.1 Gy), increased sparing

substructure segmentations work on CT‐SIM image inputs. Alto-

after beam angle modiﬁcation was possible (mean reduction in mean

gether, the results presented in this work are applicable to a variety

dose over all substructures: 1.0 ± 1.4 Gy). For example, the mean

of settings, tumor sites, breathing states, and fractionation schedules,

dose to the pulmonary vein was only reduced by 0.2 Gy after re‐op-

which appear promising for future work in cardiac sparing.

timization but was further reduced by another 1.1 Gy after beam

We have also shown here that negligible increases in treatment

angle modiﬁcation. Moreover, beam angle modiﬁcation allowed for

time per fraction and MUs delivered after plan re‐optimization were

further sparing of the LADA and LA with mean dose reductions of

observed, suggesting similar complexity of the radiation treatment

0.9 and 0.8 Gy, respectively, as compared to the SPARE plan.

plan. Moreover, even though the modiﬁed beam angles plans
involved either adding or removing beams in the revised treatment
plan, the differences in treatment time per fraction and MUs deliv-

4 | DISCUSSION

ered were negligible (P < 0.05). This shows that there will be a negligible practical penalty at the machine for incorporating cardiac

This work introduced cardiac substructures into CT‐based treatment

substructures in the treatment planning process.

planning incorporating a co‐registered low‐ﬁeld MRI to quantify

We also found that modifying the beam angle and number of

potential dosimetric advantages for improved cardiac sparing. This

beams used to consider cardiac substructures after the plan had

was completed through the retrospective re‐optimization of treat-

been re‐optimized also had the potential to increase cardiac sub-

ment plans, as well as modifying the original beam angle arrange-

structure radiation sparing. However, much like the ﬁndings by Les-

ment to minimize cardiac substructure radiation dose, all while

ter et al.,36 the results were patient speciﬁc as lesion location and

attempting to maintain PTV coverage and continuing to meet clinical

proximity to the heart and its substructures played a role in if the

endpoints for other critical OARs.

patient would beneﬁt from plan re‐optimization and beam modiﬁca-

Even though current cooperative trials use volumetric measures

tion. Patients that beneﬁted from beam angle modiﬁcation varied in

based only on MHD endpoints,29,34 introducing cardiac substructure

both the number of beams added or removed and in the proximity

segmentation into radiation treatment planning may help better

of the lesion to the heart (i.e., directly adjacent). So, although beam

study and deﬁne radiation‐induced cardiac injury. Some studies have

angle modiﬁcation was shown to provide improvements over solely

aimed to investigate the dosimetric impact of different types of ther-

re‐optimizing the plan for select cases (4/16 cases), re‐optimization

apy on cardiac substructure sparing. A study by Ferris et al.35 evalu-

alone provided the majority of cardiac substructure sparing, and thus

ated

volumetric

we have shown that simply including substructures in the optimiza-

modulated arc therapy (VMAT) and intensity modulated proton ther-

tion will provide beneﬁt to a large portion of patients. We found

apy (IMPT) and found that cardiac‐optimized plans led to statistically

that tumor location also plays a role in the extent a substructure is

signiﬁcant improvements in mean dose to the chambers, great ves-

able to be spared, regardless of plan geometry. For example, the LA

sels, and coronary arteries. Our ﬁndings agree with Ferris et a.l with

for Patient 2 was directly adjacent to the tumor volume yet the

respect to signiﬁcant reductions in the maximum dose to the LADA

mean dose difference after re‐optimization of the LA as shown in

cardiac

substructure

sparing

for

optimized

and RV (>4 Gy on average) while maintaining or improving clinical

Fig. 2 revealed only minor improvement (<1 Gy) was possible. Thus,

OAR (e.g., lung, esophagus, and spinal cord) constraints and PTV

this suggests that sparing substructures closer to the tumor volume

coverage. Likewise, Lester et al.36 created re‐optimized VMAT plans

may be difﬁcult although accurately quantifying the dose to sub-

to reduce radiation dose to the coronary arteries and cardiac valves.

structures still offers value for clinical risk assessment.

At present, few studies have integrated cardiac substructures

It is worth noting that although there was a statistically signiﬁ-

into treatment planning optimization. Ferris et al. evaluated cardiac

cant sparing of mean dose to the heart achieved after plan re‐opti-

spared plans using VMAT and IMPT with CT for locally advanced

mization, this may be due to the added weight in the optimizer for

non‐small lung cancer patients with a conventional fractionation to

when all the substructures are included. However, Fig. 4 highlights

35

Lester et al. focused on

that standard whole heart dose metrics were not sensitive to a car-

cardiac spared planning for mediastinal lymphomas by incorporating

diac sparing treatment planning approach, whereas individual sub-

60 Gy under free‐breathing conditions.

ECG‐gated CT and coronary angiography acquired at deep inspira-

structure endpoints clearly identiﬁed dosimetric, and clinically

tion breath hold.36 These patient populations were different from

meaningful gains (i.e., associated with clinical outcomes). Further-

the present study of 11 out of 16 lung cancer stereotactic body

more, the insufﬁciency of quantifying the MHD alone has been

radiation therapy cases (3‐4 fractions) with 7 end‐exhalation, 7 end‐

recently afﬁrmed by studies recommending the inclusion of cardiac

inhalation, 2 free‐breathing to test different conditions. In addition,

substructures as RT treatments become more conformal (i.e., inten-

the present study incorporated a low‐ﬁeld MRI as an adjunct to

sity modulated RT).15,37 For example, the LV‐V5, which has been

treatment planning CTs whereas the Lester et al. study used CT

shown to be more predictive of acute cardiac events than mean

angiography. While MRgRT was employed in this work, the dosime-

heart dose,6 was reduced ~15% and the mean dose to the AA was

try strategies of re‐optimization using cardiac substructures and

reduced by ~6 Gy, suggesting that with conﬁrmation in a larger

beam angle arrangement modiﬁcation are applicable to other x‐ray‐

cohort, further sparing may offer potential for improved survival.10
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This underscores the importance of using more sensitive metrics for

via daily online MR‐guided adaptive radiation therapy. Validation in a

dose evaluation and not simple whole‐heart evaluations that are cur-

larger cohort with appropriate margins will offer the potential to

rently being implemented.

reduce radiation‐related cardiac toxicities and the dose assessment

Respiratory motion was managed via breath‐holding for the

of currently overlooked radiosensitive substructures.

majority of the patients. At breath‐hold, there is still the potential
impact of cardiac motion which was not accounted for in this study
due to not having cardiac‐gated 0.35T MR‐linac images. It has been
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that use CT as the treatment planning input, this study may provide
a gateway to automatic re‐segmentation and daily adaptive planning
with MRgRT in hypofractionated and stereotactic body radiation
therapy (SBRT) treatments. An application to adaptive planning
would allow the employed cardiac substructure dose sparing measures to be maintained throughout treatment.
Finally, increasing the size of the patient cohort with varied target
locations will help identify the patient geometries that will beneﬁt
most from cardiac substructure sparing, as discussed above. However,
the size of the patient cohort in the current study is consistent with
the previously mentioned studies where 7–8 patients were used.36,39
An increase of size such as this could be completed through applying
this work to a prospective clinical trial, like that of Jacob et al,41 or be
applied to multi‐institutional studies, such as the study recently completed by Dess et al.,42 and could also help to determine if cardiac substructure dosimetric sparing has an effect on clinical outcomes.

5 | CONCLUSION
This work applied a multimodality imaging and contouring workﬂow
to showcase the possibility of providing robust dose sparing of cardiac substructures with MRgRT. New treatment plans maintained
PTV and OAR doses and did not substantially increase delivery time
or required monitor units, suggesting stable plan quality and a negligible increase in plan complexity when cardiac substructure sparing
was introduced. This study emphasized how high‐quality cardiac substructure segmentations and sparing plans may be generated at low‐
ﬁeld MRI, which offers strong potential for lower substructure doses
at initial planning and the ability to further maintain that condition
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